Please assess the completion status of the following clinical trial:

Trial Title: Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria~* Patients who are aged 18 years or older at informed consent~* Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.~Exclusion Criteria:~* Patients who fall under a contraindication listed in the blonanserin (LONASEN) package insert~* Patients with Parkinson disease~* Patients who previously received blonanserin, etc.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DSP-5423P Placebo (Type: PLACEBO_COMPARATOR): Percutaneous DSP-5423P Placebo was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P 40mg (Type: EXPERIMENTAL): Percutaneous DSP-5423P 40mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P 80mg (Type: EXPERIMENTAL): Percutaneous DSP-5423P 80mg was applied once daily for 6 weeks during the double-blinded treatment phase. Subjects who completed the double-blind treatment phase were able to entere the open-label treatment phase. The study drug was applied to the back, chest, or abdomen.
- DSP-5423P Placebo-to-Flex (Type: EXPERIMENTAL): Percutaneous Subjects received DSP-5423P Placebo once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.
- DSP-5423P Active-to-Flex (Type: EXPERIMENTAL): Percutaneous Subjects received DSP-5423P 40mg or 80mg once daily for 6 weeks in the double-blind treatment phase. In the open-label treatment phase, DSP-5423P was applied as flexible dose (40, 60, or 80 mg) once daily for 28 weeks (outside Japan) or 52 weeks (in Japan). The study drug was applied to the back, chest, or abdomen.

Based on this trial design, predict the completion outcome and termination type (if applicable).